273914 PRE-EMPT (PRE-eclampsia, Eclampsia: Monitoring, Prevention and Treatment) Initiative: An Overview

Tuesday, October 30, 2012 : 9:45 AM - 10:00 AM

Beth Payne , Child and Family Research Centre, University of British Columbia, Vancouver, BC, Canada
     
Pre-eclampsia and eclampsia remain among the top three causes of direct maternal death and morbidity, globally. The majority of deaths resulting from pre-eclampsia occur in low and middle income countries (LMICs) as a result of delays in triage, transport and treatment.

The PRE-EMPT initiative is a program of five interrelated projects aimed at addressing the need for improved monitoring, prevention and treatment strategies for women with pre-eclampsia in LMICs. One major component of this initiative is the development and validation of the miniPIERS (Pre-eclampsia Integrative Estimate of RiSk) model. The miniPIERS model is a clinical outcome prediction model that will provide accurate prediction of risk of complications in women with pre-eclampsia in order to improve triage and transport times.

This model will be used as part of a package of care in the CLIP (Community Level Interventions for Pre-eclampsia) cluster RCT, currently being planned as part of the PRE-EMPT initiative.

Learning Objectives:
1. To provide an overview of the 5 on-going projects within the PRE-EMPT initiative 2. To present initial results of the miniPIERS study highlighting lessons learned and planned steps for implementation of the model

Keywords: Maternal and Child Health, Maternal Care

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I have been the coordinator of multiple federal and NGO funded health services and epidemiological studies of pre-eclampsia. My thesis work as a graduate student has been the development and validation of clinical risk prediction models for women with pre-eclampsia.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

Back to: 4046.0: International Maternal, Neonatal & Child Health